PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast - Adrian Hernandez, MD, MHS - Recognizing and Treating Iron Deficiency in Patients With Heart Failure: Achieving Better Outcomes and Quality of Life

Adrian Hernandez, MD, MHS - Recognizing and Treating Iron Deficiency in Patients With Heart Failure: Achieving Better Outcomes and Quality of Life

07/01/19 • 17 min

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Go online to PeerView.com/FCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in cardiology shares insight on recognizing and treating iron deficiency in patients with heart failure to achieve better outcomes and quality of life. Upon completion of this activity, participants should be better able to: Recognize the prevalence of iron deficiency (ID) in heart failure (HF) and its impact on patient outcomes and quality of life, Identify evidence-based guidelines and the latest clinical data on the efficacy and safety of currently available and emerging iron therapies for the management of ID in patients with HF, Apply evidence-based guidelines and the latest clinical data on available and emerging iron therapies to the treatment of ID in patients with HF.

Previous Episode

undefined - Jay B. Wish, MD - Addressing Unmet Needs in Managing Anemia in Chronic Kidney Disease: A Closer Look at the Clinical Potential of HIF-PH Inhibitors

Jay B. Wish, MD - Addressing Unmet Needs in Managing Anemia in Chronic Kidney Disease: A Closer Look at the Clinical Potential of HIF-PH Inhibitors

Go online to PeerView.com/NWK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in nephrology discusses addressing the unmet needs in managing anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants should be better able to: Recognize the burden of anemia in patients with chronic kidney disease, Describe the pathophysiology of anemia in chronic kidney disease, focusing on current and emerging targets for therapeutic intervention, Summarize benefits and limitations associated with current approaches to treat anemia in chronic kidney disease, Describe emerging HIF-PH inhibitors in the context of mechanism of action, efficacy, safety, and potential clinical utilization.

Next Episode

John B. Buse, MD, PhD - An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Disease in Patients With Type 2 Diabetes

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.